This article is a review of immunotherapy in the treatment of cancer incorporating the history of immunotherapy in the nineteenth and twentieth centuries, assessment of the techniques currently in use and of possible future developments.
Although immunotherapy is not established as a therapeutic technique, evidence suggests that the immune response does influence the development of neoplastic cells. A better understanding of the immune response and its control may lead to the production of efficacious immunological treatment of certain cancers.
Get full access to this article
View all access options for this article.
References
1.
AlexanderP.DelorméE. J. (1971). Use of irradiated immune lymphoid cells for immunotherapy of primary tumours in rats. Israeli Journal of Medical Science, 7, 239
2.
AlexanderP. (1972). Foetal antigens in cancer. Nature, 235, 137
3.
AmeryW. (1975). Levamisole. Lancet1, 389
4.
AmosD. B.PrioleanW. H.HutchinP. (1968). Histochemical changes during growth of CH3 ascites tumour B.P.8 in C57 mice. Effects of enhancing antiserum. Journal of Surgical Research, 8, 122
5.
BaldwinR W.PriceM. R.RobinsR. A. (1973). Inhibition of hepatoma-lymph node cell cytoxicity by tumour bearer serum and solubilised hepatoma antigen. International Journal of Cancer, 11, 527
6.
BastR. C.Jr.ZbarM.BorosT.RappH. J. (1974). B.C.G. and cancer. New England Journal of Medicine, 290, 148
7.
BerkeleyW. N. (1914). Results of 3 years' observation on a new form of cancer treatment. American Journal of Obstetric Diseases of Women, 69, 1061
8.
BluntingA. Z.VogelC. L.ZeiglerJ. L.ModyN.KamyaG. (1972). Immunological effects of BCG in malignant melanoma: modes of administration compared. Annals of Internal Medicine, 76, 405
9.
BoeriD. G. (1901). Europathologie: recherches cliniques sur la respiration, sur le rire, sur le pleurer et sur le baillement des hemiplegiques. Gazette Hebdomadaire de Medecine et de Chirurgie
10.
BorbergH.OettgenH. F.ChoudryK.BeatyE. J. (1972). Inhibition of established transplants of chemically induced sarcomas in syngenic mice by lymphocytes from immunised donors. International Journal of Cancer, 10, 539
11.
BrandesL. J.CaltonD. A. G. (1971). A new approach to immunotherapy of melanoma. Lancet, 2, 293
12.
BraunW.IshizukeM.YajimaT.WebbD.WinchurchR. (1971). In Biological effects of polynucleotides, p. 139. Edited by BeersR. F.BraunW.. New York: Academic Press
13.
CastroJ. E.SadlerT. E.JonesP. (1976). Immunological mechanisms involved in the inhibition of tumour metastases byC. parvum. British Journal of Surgery, 63, 153
14.
CocaA. F.DorranceG. M.LebredoM. G. (1912). ‘Vaccination’ in cancer. A report on the results of vaccination therapy as applied in 79 cases of human cancer. Zeitschrift fur Immunitatsforschung und Experimentelle Therapie, 13, 543
15.
CocaA. F.GillmanG. (1909). The spscific treatment of carcinoma. Philippine Journal of Science (Medical section), 4, 381
16.
CunninghamT. J.OisenK. B.LaftinR.HortonJ. C.Sullivan (1969) Treatment of advanced cancer withactive immunisation. Cancer, New York24, 922
17.
CurrieG. A. (1970). The sugar coated cancer cell. The role of sialic acid in antigenic aggression in immunology and tolerance in oncogenesis. Proceedings IVth Perugia Quadrennial International Conference on Cancer, p. 893
18.
CurrieG. A. (1972). Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. British Journal of Cancer, 26, 141
19.
CurrieG. A.BagshaweD. L. (1968). Role of sialic acid in antigenic expression. Further studies of Landschultz ascites tumour. British Journal of Cancer, 22, 843
20.
CurrieG. A.BagshaweD. L. (1969). Tumour specific immunogenicity of methylcholanthrene induced sarcoma cells after incubation in neuraminidase. British Journal of Cancer, 23, 141
21.
CurrieG. A.BagshaweD. L. (1970). Active immunotherapy with C parvum and chemotherapy in murein fibrosarcomas. British Medical Journal, 1, 541
22.
CurrieG. A.BashamG. (1972). Serum-mediated inhibition of the immunological reactions of the patient's own tumour: a possible role for circulating antigen. British Journal of Cancer, 26, 427
23.
EdwardsF. R.WhitewellF. (1974). Use of BCG as an immunostimulant in the surgical treatment of carcinoma of the lung. Thorax, 29, 654
24.
EilberF. R.MortonD. L.HolmesE. C.SparksF. CRammingK. P. (1976). Immunotherapy with BCG for lymph node metastases for malignant melanoma. New England Journal of Medicine, 296, 237
25.
EpsteinM. A.AchongB. G. (1973). Various forms of Epstein-Barr virus infection in man. Established facts and general conflict. Annual Review of Microbiology, 27, 413
26.
FassL.HerbmannR. B.ZeiglerR.MorrowR. H. (1970). Evaluation of the effect of remission plasma on untreated patients with Burkitt's lymphoma. Journal of National Cancer Institute, 44, 145
27.
FeldmannJ. D. (1973). Immunological enhancement: a study of; blocking antibodies. Advances in Immunology, 15, 167
28.
FinkM. P.ParkerC. W.ShearerW. T. (1975). Antibody stimulation of tumour growth in T-cell depleted mice. Nature, 255, 137
29.
FolkmannJ. (1976). The vascularisation of tumours. Scientific American, 234, 58
30.
GershonR. K.EardleyD. D.PtakW. (1975). Functional inactivation of suppressor T-cells by heat-killed macrophages. Nature, 262, 216
31.
GirmanG.PeesH.SchwatzG.ScheurlenP. G. (1976). Immunosuppression by micromobcular fibrinogen degradation products in cancer. Nature, 259, 399
32.
GhoseT.NorvellS. T.GuclaA.CameronD.BodurthaA.McDonaldA. S. (1972). Immunotherapy of cancer with chlorabucil-carrying antibody. British Medical Journal, 3, 495
33.
GoldenbergG. J.BrandesL. J., (1976). In vivo and In vitro studies of immunotherapy of nasopharyngeal carcinoma with transfer factor. Cancer, Research, 36, 720
34.
GuthrieD.WayS. (1975). Immunotherapy of nonclinical vaginal cancer. Lancet, 2, 1242
35.
HaddowA.AlexanderP. (1964). An immunological method of increasing the sensitivity of primary sarcomas to local irradiation with X-rays. Lancet, 1, 462
36.
HalpernB. N.PrevotA. R.BiozziG.StiffelCMoutonD.MorardJ. G.BouthillierT.DecreasefordC. (1963). Stimulation de l'actívité phagocytaire du Systeme reticulcendothelial provoqué parC. parvum. Journal of Reticuloendothelial Society, 1, 77
37.
HamiltonD. N. H.BellP. R. F. (1974). Immunotherapy of Moloney sarcoma virus tumours in mice withC. parvum. British Journal of Surgery, 61, 321
38.
HellstromI.HellstromK. E. (1971). Cellular immunity and blocking antibody to tumours. Reticulo-endothelial Society, 10, 131
39.
HellstromK. E.HellstromI. (1969). Cellular immunity against tumour antigens. Advances in Cancer Research, 12, 167
40.
HellstromK. E.HellstromI. (1970). Immunological enhancement as studied by cell culture techniques. Annual Review of Microbiology, 24, 373
41.
HenléW.HenléG.HoH. CBurlinP.CachanT.CliffordP.de SchryverA.deThéDiehlV.KleinG. (1970). Antibody to Epstein-Barr virus in nasopharyngeal carcinoma. Journal of National Cancer Institute, 44, 225
42.
Hericourt and Richet (1895). Physiologie, pathologique de la seropathie dans le traitment du cancer. Compte Rendu Academie Sciences (Paris)), 121, 567
43.
HumphreyL. J.JewellW. R.MurrayO. R.GriffenW. O. (1971). Immunotherapy for the patient with cancer. Annals of Surgery, 173, 47
44.
JamiesonC. W.DouglasS.SigginsS.DesaiS. (1974). Increase in antigenicity of syngeneic mice melanoma by neuraminidase. British Journal of Surgery, 61, 321
45.
JarrettW.MackayL.JarrettO.LairdH.HoodC. (1974). Antibody response and viral survival in cats vaccinated against feline leukaemia. Nature, 248, 230
46.
KalissN. (1958). Immunological enhancement of tumour homografts in mice. Cancer Research, 18, 992
47.
KleinG. (1968a). Tumours of skin. X. Immunotherapy of cutaneous and mucosal neoplasmas. New York State Journal of Medicine, 68, 900
48.
KleinG. (1968). Tumour specific transplantation antigens. Cancer Research, 28, 625
49.
LaufsR.SteinkeH. (1975). Vaccination of non-human primates against malignant lymphoma. Nature, 253, 70
50.
LawrenceH. S. (1969). Transfer Factor. Advances in Immunology, 11, 195
51.
Le Bertrand (1909)… Quoted from Southam, C. M. (1961). Applications of immunology to clinical cancer: past attempts and future possibilities. Cancer Research, 21, 1302
52.
LevinA. S.SpitlerL. E.FudenbergH. H. (1973). Transfer factor therapy in immune deficiency states. Annual Review of Medicine, 24, 175
53.
LevyR.HurwitzE.MaronR.ArnonR.SelaM. (1975). The specific cytotoxic effects of daunomycin conjugated to anti-tumour antibodies. Cancer Research, 35, 1186
54.
LikhiteV. V. (1976). Suppression of incidence of death from spontaneous tumours in DBA/2 mice after C. parvum mediated rejection of syngeneic tumour. Nature, 251, 397
55.
McBrideW. H.DawesJ.TuachS. (1976). Anti-tumour activity of C. parvum extracts. Journal of National Cancer Institute, 56, 437
56.
McGregorA. B.FalkR. E. (1976). Immunotherapy of malignant disease (Part 2). Journal of the Royal College of Surgeons, Edinburgh, 21, 43
57.
McNeallyM. F.MaverCKauselH. W. (1976). Regional immunotherapy of lung cancer with intra-pleural BCG. Lancet, 1, 377
58.
MastrangeloM. S.SulitH. CPrehnL.BernsteinR. S.YarbroJ. W.PrehnR. T. (1976). Intra-lesional BCG in the treatment of malignant melanoma. Cancer, 37, 684
59.
MathéG. (1970). Immunological treatment of leukaemia. British Medical Journal, 4, 487
60.
MathéG. (1976). Introduction to active immunotherapy of cancer. In press
61.
MathéG.AmielS. L.SchwartzenbergL.SchneiderM.ÇattanA.SchlumbergerJ. L.HayatM.ReVassalF. (1969). Active immunotherapy for acute lymphoblastic leukaemia. Lancet, 1, 697
62.
MathéG.SchwartzenbergL.DeVassalF.DelgadoM. (1976). Immunotherapy for acute lymphoid leukaemia. Lancet, 1, 143
63.
Medical Research Council (1971). Report on the treatment of acute lymphoblastic leukaemia (1971). Comparison of immunotherapy (BCG), intermittent methotrexate and no therapy after a 5-month cytotoxic regimen. British Medical Journal, 4, 189
64.
MooltenF. L.CapparellN. J.ZaydelS. H.CooperbandS. R. (1975). Anti-tumour effects of antibody-diphtheria toxin conjugates. II Immunotherapy with conjugates directed against tumour antigens induced by simian virus 40. Journal of National Cancer Institute, 55, 473
65.
MooreG. E. (1975). Rationale for cancer immunotherapy. Journal of American Medical Association, 231, 1186
66.
MorseT. S. (1973). The American Trauma Society—lessons learned from cancer and coronaries. Surgery, 73, 806
67.
MortonD. L.EilberF. R.MalingrenR. A.WoodW. C. (1970). Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery, 68, 158
68.
MortonD. L.HolmesE. CEilberF. R.WoodW. C. (1971). Immunological aspects of neoplasia. A rational basis for immunotherapy. Annals of Internal Medicine, 74, 587
69.
NadlerS. H.MooreG. E. (1966). Clinical immunological study of malignant disease: response to tumour transplants and transfer of leucocytes. Annals of Surgery, 164, 482
70.
NadlerS. H.MooreG. E. (1969). Immunotherapy of malignant disease. Archives of Surgery, 99, 376
71.
NathanC. F.HillV. M.TerryW. D. (1976). Isolation of sub-population of adherent peritoneal cells with anti-tumour activity. Nature, 260, 146
72.
OettgenH. E.OldL.FarrowJ.ValentineF.LawrenceS.ThomasS. (1971). Effects of transfer factor in cancer patients. Journal of Clinical Investigation, 50, 71a
73.
PilchY. P.RammingK. P.DeckersP. J. (1973). Induction of anti-cancer immunity with RNA. Annals of New York Academy of Science, 207, 409
74.
PinesA. (1976). A 5-year controlled study of BCG and radiotherapy for inoperable lung cancer. Lancet, 1, 380
75.
PowlesR. (1972). Investigation and stimulation of immunity in cancer patients. In The Investigation and Stimulation of Immunity in Cancer Patients Edited by PowlesR.. New York: Academic Press
76.
PowlesR.CrowtherD.BatemanC. J.BeardM. E.McElwhainT. J.RusselJ.ListerT. A.WhitehouseJ. M. A.WrigleyP. F. M.PikeM.AlexanderP.Hamilton-FairleyG.(1). Immunnotherapy for acute myelogenous leukaemia. British Journal of Cancer, 28, 356
77.
PragerM. D.BaechtelF. S. (1973). Methods for modification of cancer cells to enhance the immunogenicity. In Methods in Cancer Research. p.339. Edited by BuschH.. New York: Academic Press
78.
PrehnR. T. (1972). The immune reaction as a stimulation of tumour growth. Science, 176, 170
79.
RappF.BussE. R. (1974). Are viruses important in carcinogenesis?American Journal of Pathology, 77, 85
80.
RojasA. F.MickiwiczE.FeiersteinJ. N.GlaitH.OlwariA. J. (1976). Levamisole in advanced human breast cancer. Lancet, 1, 211
81.
RowlandG. F.O'NeillG. J.DaviesD. A. L. (1975). Suppression of tumour growth in mice by a drug antibody conjugate using a novel approach to linkage. Nature, 255, 487
82.
ScottM. I. (1974). C. parvum as a therapeutic anti-tumour agent in mice. II. Local injection. Journal of National Cancer Institute, 53, 861
83.
SimmonsR. L.RiosA. (1972). Immunospecific regression of methylcholanthrene fibrosarcoma using neurominidase. II. Intra-tumour injection of neurominidase. Surgery, 71, 556
84.
SimmonsR. L.RiosA.LundgreenG.RayP. K.McKhannC. F.HaywoodG. R. (1971). Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neurominidase. Surgery St. Louis, 70, 38
85.
SokalJ. E.AunstC. W.SnydermanM. (1974). Delay in progression of malignant lymphoma after BCG vaccination. New England Journal of Medicine, 291, 1226
86.
SjögrenH. O.HellstromI.BansalM. CHellstromK. E. (1971). Suggestive evidence that the ‘Blocking Antibodies’ of tumour bearing individuals may be Antibody-Antigen Completes. Proceedings of the National Academy of Science U.S.A.681972
87.
SuitH. D.SedlacekR.WagnerM.OrsiL. (1975). Radiation response of C3H fibrosarcoma enhanced in mice stimulated byC. parvum. Nature, 255, 493
88.
SymesM. O.RiddellA. G. (1973). The use of immunised pig lymph node cells in the treatment of patients with advanced malignant disease, British Journal of Surgery, 60, 176
89.
ThomasL. (1959). In Cellular and Humoral aspects of the Hypersensitive States, p. 529. Edited by LawrenceH. S.. New York: Hoebner
90.
VidalE. (1911). Travaux de la 2° Conference Internationale por Vetudé du Cancer. La Serotherapies des tumeurs malignes. Paris1910, p.293
91.
VoglerW. R.ChanY. K. (1974). Prolonging remission in myeloblastic leukaemia by Tice strain Bacille Calmette-Guerin. Lancet, 2, 128
92.
VoisinG. A. (1971). Immunological facilitation: a broadening of the concept of the enhancement phenomenon. Progress in Allergy, 15, 328
93.
Von LeydenV. E.BlumenthalF. (1902). Vorlautige Mittheilinger uber einige Ergebnisse der Krebsforschung auf der medizinischen Klinic. Deutsche Medizinische Wochenschrift, 28, 637
94.
WimerB. W. (1976). Remission of lymphoblastic leukaemia. Lancet, 1, 316
95.
Wong-StahlF.GillespieD.GalloR. C. (1976). Proviral sequence of baboon endogenous C type RNA virus in DNA of human leukaemic tissue. Nature, 262, 190
96.
WoodruffM. F. A. (1975). Tumour inhibitory properties of anaerobic Corynebacteria. Transplantation Proceedings, 7, 229
97.
WoodruffM. F. A.BoakJ. L. (1966). Inhibitory effect of C. parvum on the growth of tumour transplants in isogenic hosts. British Journal of Cancer, 20, 345
